Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS -2.06%19 PB Ratio is 1.74 as of Aug. 14, 2026, which is 62% below its 10-year median of 4.55. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Curis Lifesciences ranks better than 55.6% on this metric.
The historical rank and industry rank for Curis Lifesciences's PB Ratio or its related term are showing as below:
NSE:CURIS'
s PB Ratio Range Over the Past 10 Years
Min: 1.54 Med: 4.55 Max: 7.02
Current: 1.74
During the past 4 years, Curis Lifesciences's highest PB Ratio was 7.02. The lowest was 1.54. And the median was 4.55.
NSE:CURIS's PB Ratio is ranked better than 55.6% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs NSE:CURIS: 1.74
During the past 12 months, Curis Lifesciences's average Book Value Per Share Growth Rate was 191.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 261.10% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Curis Lifesciences was 261.10% per year. The lowest was 261.10% per year. And the median was 261.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Curis Lifesciences PB Ratio Related Terms
Curis Lifesciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences PB Ratio Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
PB Ratio
0.00
0.00
0.00
1.59
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
PB Ratio
0.00
0.00
0.00
1.59
NSE:CURIS vs ZTS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Curis Lifesciences (NSE:CURIS) has a PB Ratio of 1.74 as of Aug. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curis Lifesciences and its competitors. This is 62% below median its historical median of 4.55. Over the past decade, Curis Lifesciences' PB Ratio has ranged from 1.54 to 7.02. According to the industry distribution chart, Curis Lifesciences ranks #408 out of 919 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Curis Lifesciences' PB Ratio too high?
Curis Lifesciences' current PB Ratio of 1.74 is 62% below median its 10-year median of 4.55. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 7.02. The Drug Manufacturers industry median PB Ratio is 1.98. Curis Lifesciences' value of 1.74 is 12.1% below this industry median. Based on the distribution chart, Curis Lifesciences ranks #408 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #408 out of 919 companies for PB Ratio. This puts Curis Lifesciences in the upper half of its industry. The industry median PB Ratio is 1.98. Curis Lifesciences' value of 1.74 is 12.1% below this benchmark. Historically, Curis Lifesciences' own PB Ratio has ranged from 1.54 to 7.02 over the past decade. While the company's 10-year median is 4.55 vs. the industry median of 1.98, Curis Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current PB Ratio of 1.74 is 12.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current PB Ratio is 1.74, which is 62% below median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current PB Ratio of 1.74. The current PB Ratio is 1.74, which is 62% below median its 10-year median of 4.55 and 12.1% below the Drug Manufacturers industry median of 1.98. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current PB Ratio is 1.74 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
